Why natural killer cells react to COVID-19
Little has been known to date about how the immune system’s natural killer (NK) cells detect which cells have been infected with SARS-CoV-2. An international team of scientist led by researchers from Karolinska Institutet in Sweden now shows that NK cells respond to a certain peptide on the surface of infected cells. The study, which is published in Cell Reports, is an important piece of the puzzle in our understanding of how the immune system reacts to COVID-19.
NK cells are white blood cells that are part of the innate immune system. Unlike cells in the adaptive immune defence, they are able to recognise and kill cancer cells and virus-infected cells immediately without having encountered them before. This ability is controlled by a balance between the NK cells’ activating and inhibiting receptors, which can react to different molecules on the surface of other cells.
The virus is revealed by a peptide
A new study shows why certain NK cells are activated when encountering a cell infected with SARS-CoV-2. The infected cells contain a peptide from the virus that triggers a reaction in NK cells that carry a particular receptor, NKG2A, able to detect the peptide.
“Our study shows that SARS-CoV-2 contains a peptide that is displayed by molecules on the cell surface,” says Quirin Hammer, researcher at the Center for Infectious Medicine (CIM), Karolinska Institutet. “The activation of NK cells is a complex reaction, and here the peptide blocks the inhibition of the NK cells, which allows them to be activated. This new knowledge is an important piece of the puzzle in our understanding of how our immune system reacts in the presence of this viral infection.”
The study was a major collaboration between Karolinska Institutet, Karolinska University Hospital and research laboratories and universities in Italy, Germany, Norway and the USA. The first phase was to test their hypothesis using computer simulations that were then confirmed in the laboratory. The decisive phase was the infection of human lung cells with SARS-CoV-2 in a controlled environment, whereupon the researchers could show that NK cells with the receptor in question are activated to a greater degree than the NK cells without it.
Monitoring new virus variants
“These findings are important to our understanding of how immune cells recognise cells infected with SARS-CoV-2,” says Dr Hammer. “This may become significant when monitoring new virus variants with the aim to determine how well the immune system responds to them.”
The study is now being followed up with the help of a biobank at Karolinska University Hospital and Karolinska Institutet containing blood samples from over 300 people treated for COVID-19 during the first wave of the pandemic.
“We’ll be examining if the composition of NK cells a person has contributes to how severe their symptoms are when infected with SARS-CoV-2,” he continues.
The study was financed by the EU, Deutsche Forschungsgemeinschaft (DFG), the Karolinska Institutet Foundation for Virus Research, the Petrus and Augusta Hedlund Foundation, the Clas Groschinsky Memorial Foundation, the Lars Hierta Memorial Foundation, the Tornspiran Foundation, the Swedish Cancer Society, the Norwegian Research Council, the Swedish Research Council, the Knut and Alice Wallenberg Foundation and Nordstjernan AB. Co-author Hans-Gustaf Ljunggren is a member of the board of XNK Therapeutics AB and Vycellix Inc. Karl-Johan Malmberg is scientific advisor for and has a research grant from Fate Therapeutics, and is a member of Vycellix Inc’s scientific advisory board.
Publication: “SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells”. Quirin Hammer, Josefine Dunst, Wanda Christ, Francesca Picarazzi, Mareike Wendorff, Pouria Momayyezi, Oisín Huhn, Herman K. Netskar, Kimia T. Maleki, Marina García, Takuya Sekine, Ebba Sohlberg, Valerio Azzimato, Myriam Aouadi, Karolinska COVID-19 Study Group, Severe COVID-19 GWAS group, Frauke Degenhardt, Andre Franke, Francesco Spallotta, Mattia Mori, Jakob Michaëlsson, Niklas K. Björkström, Timo Rückert, Chiara Romagnani, Amir Horowitz, Jonas Klingström, Hans-Gustaf Ljunggren and Karl-Johan Malmberg. Cell Reports, online 20 February 2022, doi: 10.1016/j.celrep.2022.110503.
For more information, please contact:
Quirin Hammer, researcher
Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet
Phone: +46 (0)79-304 24 71
Email: quirin.hammer@ki.se
Karolinska Institutet is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Tags:
